Abbott Laboratories (ABT) Competitors $128.76 +1.22 (+0.96%) As of 02:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABT vs. DXCM, ISRG, TSLA, ABBV, BSX, ELV, ITGR, JNJ, MDT, and TMOShould you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include DexCom (DXCM), Intuitive Surgical (ISRG), Tesla (TSLA), AbbVie (ABBV), Boston Scientific (BSX), Elevance Health (ELV), Integer (ITGR), Johnson & Johnson (JNJ), Medtronic (MDT), and Thermo Fisher Scientific (TMO). Abbott Laboratories vs. Its Competitors DexCom Intuitive Surgical Tesla AbbVie Boston Scientific Elevance Health Integer Johnson & Johnson Medtronic Thermo Fisher Scientific DexCom (NASDAQ:DXCM) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Which has more risk and volatility, DXCM or ABT? DexCom has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Does the media prefer DXCM or ABT? In the previous week, Abbott Laboratories had 103 more articles in the media than DexCom. MarketBeat recorded 122 mentions for Abbott Laboratories and 19 mentions for DexCom. Abbott Laboratories' average media sentiment score of 0.84 beat DexCom's score of 0.66 indicating that Abbott Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 10 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abbott Laboratories 59 Very Positive mention(s) 9 Positive mention(s) 21 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend DXCM or ABT? DexCom currently has a consensus target price of $96.40, indicating a potential upside of 36.83%. Abbott Laboratories has a consensus target price of $147.00, indicating a potential upside of 14.28%. Given DexCom's higher probable upside, research analysts plainly believe DexCom is more favorable than Abbott Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 0 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.88Abbott Laboratories 0 Sell rating(s) 4 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.91 Is DXCM or ABT more profitable? Abbott Laboratories has a net margin of 31.88% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Abbott Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets DexCom13.29% 30.41% 10.08% Abbott Laboratories 31.88%17.78%10.64% Which has higher earnings and valuation, DXCM or ABT? Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDexCom$4.03B6.85$576.20M$1.4448.92Abbott Laboratories$41.95B5.34$13.40B$7.9816.12 Do insiders & institutionals believe in DXCM or ABT? 97.8% of DexCom shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAbbott Laboratories beats DexCom on 10 of the 17 factors compared between the two stocks. Get Abbott Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABT vs. The Competition Export to ExcelMetricAbbott LaboratoriesMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$223.79B$10.93B$6.24B$21.85BDividend Yield1.82%1.88%5.74%3.61%P/E Ratio16.1120.4529.1132.49Price / Sales5.3427.76552.0084.41Price / Cash19.6725.0537.4524.48Price / Book4.663.4812.314.59Net Income$13.40B$208.83M$3.33B$1.02B7 Day Performance-0.56%-3.12%-1.45%-0.75%1 Month Performance-5.99%-1.27%5.00%-0.72%1 Year Performance10.77%-9.86%61.20%10.14% Abbott Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABTAbbott Laboratories4.9709 of 5 stars$128.76+1.0%$147.00+14.2%+9.1%$224.01B$41.95B16.13114,000Earnings ReportAnalyst ForecastAnalyst RevisionDXCMDexCom4.8966 of 5 stars$66.28-2.6%$97.42+47.0%-3.9%$25.99B$4.03B46.0210,300Analyst ForecastISRGIntuitive Surgical4.6639 of 5 stars$439.88-0.9%$589.43+34.0%-10.8%$157.69B$9.15B61.3515,638Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Gap UpTSLATesla4.402 of 5 stars$426.11-2.2%$354.67-16.8%+102.2%$1.41T$97.69B245.59125,665Trending NewsAnalyst ForecastABBVAbbVie4.6164 of 5 stars$233.98+1.4%$231.90-0.9%+24.0%$412.93B$56.33B111.3155,000Trending NewsAnalyst ForecastAnalyst RevisionBSXBoston Scientific4.6093 of 5 stars$96.47-0.8%$120.71+25.1%+13.4%$142.82B$18.49B57.3753,000Trending NewsEarnings ReportOptions VolumeGap UpELVElevance Health4.8107 of 5 stars$355.11-0.8%$414.63+16.8%-17.0%$79.96B$189.25B15.11104,200Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastITGRInteger3.6449 of 5 stars$100.97-2.4%$139.57+38.2%-15.6%$3.54B$1.79B44.5011,000Upcoming EarningsAnalyst ForecastJNJJohnson & Johnson4.8972 of 5 stars$191.26+0.1%$191.41+0.1%+17.9%$460.61B$88.82B20.46138,100Positive NewsAnalyst UpgradeMDTMedtronic4.9192 of 5 stars$96.39-0.1%$101.82+5.6%+5.3%$123.63B$33.54B26.5595,000Positive NewsTMOThermo Fisher Scientific4.5947 of 5 stars$532.22-0.5%$593.43+11.5%-6.0%$200.94B$42.88B30.78125,000Trending NewsEarnings Report Related Companies and Tools Related Companies DXCM Alternatives ISRG Alternatives TSLA Alternatives ABBV Alternatives BSX Alternatives ELV Alternatives ITGR Alternatives JNJ Alternatives MDT Alternatives TMO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABT) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABT Stock Alerts